Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Damar Batu as a novel matrix former for the transdermal drug delivery: in vitro evaluation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Mundada AS;Mundada AS; Avari JG
  • Source:
    Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2009 Sep; Vol. 35 (9), pp. 1147-54.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 7802620 Publication Model: Print Cited Medium: Internet ISSN: 1520-5762 (Electronic) Linking ISSN: 03639045 NLM ISO Abbreviation: Drug Dev Ind Pharm Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: New York, Dekker.
    • Subject Terms:
      Drug Carriers/*chemistry ; Resins, Plant/*chemistry; Administration, Cutaneous ; Animals ; Chromatography, Thin Layer ; Diffusion Chambers, Culture ; Drug Carriers/adverse effects ; Drug Delivery Systems ; Drug Stability ; Irritants ; Membranes, Artificial ; Polymers ; Rats ; Rats, Wistar ; Resins, Plant/adverse effects ; Skin Absorption ; Solubility ; Spectrophotometry, Infrared ; Spectrophotometry, Ultraviolet
    • Abstract:
      Purpose: Damar Batu (DB) is a novel film-forming biomaterial obtained from Shorea species, evaluated in this study for its potential application in transdermal drug delivery system.
      Methods: DB was characterized initially in terms of acid value, softening point, molecular weight (M(w)), polydispersity index (M(w)/M(n)), and glass transition temperature (T(g)). Neat, plasticized films of DB were investigated for mechanical properties. The biomaterial was further investigated as a matrix-forming agent for transdermal drug delivery system. Developed matrix-type transdermal patches were evaluated for thickness and weight uniformity, folding endurance, drug content, in vitro drug release study, and skin permeation study.
      Results: On the basis of in vitro drug release and in vitro skin permeation performance, formulation containing DB/Eudragit RL100 (60 : 40) was found to be better than other formulations and was selected as the optimized formulation. IR analysis of physical mixture of drug and polymer and thin layer chromatography study exhibited compatibility between drug and polymer.
      Conclusion: From the outcome of this study, it can be concluded that applying suitable adhesive layer and backing membrane-developed DB/ERL100, transdermal patches can be of potential therapeutic use.
    • Accession Number:
      0 (Drug Carriers)
      0 (Irritants)
      0 (Membranes, Artificial)
      0 (Polymers)
      0 (Resins, Plant)
    • Publication Date:
      Date Created: 20090627 Date Completed: 20100105 Latest Revision: 20090817
    • Publication Date:
      20250114
    • Accession Number:
      10.1080/03639040902882249
    • Accession Number:
      19555240